Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials

@article{Martin2007ReviewBI,
  title={Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials},
  author={Jos{\'e} Luis R. Martin and Maria Sainz-Pardo and Toshiaki Furukawa and Eva Mart{\'i}n-S{\'a}nchez and Teresa Boquete Seoane and C Redondo Gal{\'a}n},
  journal={Journal of Psychopharmacology},
  year={2007},
  volume={21},
  pages={774 - 782}
}
No systematic review or meta-analysis using a hard outcome has been conducted on the role of benzodiazepines for generalized anxiety disorder (GAD). The objective of this study was to assess the effectiveness and efficacy of benzodiazepines in the treatment of GAD based on trial drop-out rates. We used a systematic review of randomized controlled trials that compared any of the three best established benzodiazepines (diazepam, Lorazepam and aLprazolam) against placebo. Our primary outcome for… 
Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorder: Systematic review and meta-analysis
TLDR
A systematic review of placebo-controlled randomized controlled trials with benzodiazepines in generalized anxiety disorder found three factors were shown to be associated statistically with change in HAM-A; baseline Hamilton Anxiety Scale (HAM-A) score, baseline anxiety level for Benzodiazepine arm and study duration, and duration of the study.
Effectiveness of benzodiazepines: do they work or not?
  • M. Lader
  • Psychology
    Expert review of neurotherapeutics
  • 2008
TLDR
The conclusion is that efficacy was significantly higher for the drugs as compared with placebo; by contrast, no convincing evidence was found of any short-term effectiveness: and adverse effects were 1.5-times more frequent in the drug-treated patients.
Evidence-based pharmacotherapy of Generalized Anxiety Disorder.
TLDR
Due to their efficacy in GAD and comorbid anxiety and depressive disorders, their tolerability and safety, certain selective serotonin re-uptake inhibitors (escitalopram, paroxetine, sertraline) should be considered the first-line treatment for most patients, although the serotonin-noradrenaline re-ptake inhibitor venlafaxine is a reasonable alternative.
Evidence-based pharmacological treatment of generalized anxiety disorder.
TLDR
It is difficult to predict reliably which patients will respond well to pharmacological treatment, but response to antidepressants is unlikely if there is no evidence of an onset of effect within 4 wk, and continuing treatment for at least 12 months is recommended.
Does initial use of benzodiazepines delay an adequate pharmacological treatment? A multicentre analysis in patients with psychotic and affective disorders
TLDR
It is suggested that initial BZDs treatment may prolong the overall DUI, although their prescription seems to be influenced by specific sociodemographic and clinical factors.
A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain.
TLDR
Starting treatment with pregabalin was associated with significant reduction in medical visits and total health care resource costs of GAD compared to SSRI/ SNRI in BR patients in the Spanish NHS setting.
Pharmacological treatment of generalized anxiety disorder.
TLDR
Treatment guidelines for GAD will be influenced by emerging data for established and novel pharmacological approaches, and possibly through the more accurate identification of certain patient subgroups who are likely to respond preferentially to particular interventions.
Should benzodiazepines still have a role in treating patients with anxiety disorders?
TLDR
Observations may be perplexing, as most guidance recommends that benzodiazepines should be prescribed for only short periods and in only a minority of patients, but evidence from pharmacoepidemiological studies and prescribing practice surveys shows that doctors are still prepared to prescribe for longer periods, even when guidance recommends against this.
Pharmacotherapy of anxiety disorders: a critical review
TLDR
A considerable database of studies shows efficacy and relative tolerability of the selective serotonin reuptake inhibitors in the major anxiety disorders, and secondary analyses of such datasets have informed questions such as optimal definition of response and remission, optimal dose and duration, and comparative efficacy of different agents.
The Pharmacologic Treatment of Patients With Generalized Anxiety Disorder: Where Are We Now and Where Are We Going?
TLDR
There is a clear need for further randomized controlled trials of augmentation treatment in patients who do not respond to SSRI, SNRI, or other initial pharmacologic approaches, and the optimal duration of treatment after a satisfactory response to acute treatment is still uncertain.
...
...

References

SHOWING 1-10 OF 44 REFERENCES
A Meta-analytic Review of the Efficacy of Drug Treatment in Generalized Anxiety Disorder
TLDR
Pharmacotherapy, especially benzodiazepines and azapirones, is effective in the short-term treatment of patients with generalized anxiety disorder and there was no superiority of 1 drug class in reducing symptomatology.
Predictors of Outcome Following Venlafaxine Extended-Release Treatment of DSM-IV Generalized Anxiety Disorder: A Pooled Analysis of Short- and Long-Term Studies
TLDR
In the largest pooled analysis to date, pretreatment factors were associated with treatment outcome in patients with GAD receiving venlafaxine XR or placebo, and the strongest trends emerged for history of substance abuse or dependence and symptoms of restlessness, sleep disturbance, and difficulty concentrating.
Selecting pharmacotherapy for generalized anxiety disorder.
  • W. Goodman
  • Psychology
    The Journal of clinical psychiatry
  • 2004
TLDR
The recent realization of the chronic nature of GAD and the recognition of its frequent comorbidity with depression, coupled with data from randomized clinical trials of newer generation agents, should help physicians better diagnose and achieve the goal of bringing patients to full remission.
Pharmacotherapy of generalized anxiety disorder.
TLDR
The most effective treatment for managing the recurrent symptoms of this chronic disorder will remain unknown until more long-term studies using both drug and nondrug therapies are conducted.
Long‐term pharmacological treatment of generalized anxiety disorder
TLDR
Only eight long‐term reports of studies conducted in well‐defined homogeneous groups of patients diagnosed with generalized anxiety disorder were found with the methodology of these studies presenting a number of limiting factors, and results are inconclusive and no reference drug could be identified.
The effects of benzodiazepines on cognition.
TLDR
Findings suggest that patients should be advised of potential cognitive effects when treated long term with benzodiazepines, although they should also be informed that the impact of such effects may be insignificant in the daily functioning of most patients.
The epidemiology of generalized anxiety disorder.
Generalized Anxiety Disorder: Acute and Chronic Treatment
TLDR
Clinical and epidemiological data suggest that generalized anxiety disorder (GAD) is a chronic illness causing patients to suffer for many years leading to significant distress in daily life functioning and research is needed in the area of developing treatment strategies for patients suffering from treatment-refractory GAD.
New evidence on benzodiazepine use and falls: the time factor.
TLDR
Results from multivariate logistic regression models showed a greater risk of falling for BZD users but the odds ratio was higher for men than for women, and a history of treatment for alcohol abuse was a very strong risk factor for falls.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
TLDR
Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
...
...